NDABUCCALTABLET
Approved
Apr 2013
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
6/8 — Strong
SITAVIG (acyclovir) by Charter Medical is dna polymerase inhibitors [moa]. Approved for herpes simplex, genital herpes, herpes labialis. First approved in 2013.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SITAVIG is a buccal tablet formulation of acyclovir, a DNA polymerase inhibitor approved in 2013 for treatment of herpes simplex labialis (cold sores). It works by inhibiting viral DNA replication, reducing viral load and symptom severity across multiple herpesvirus indications including genital herpes, herpes zoster, and emerging oncology applications.
$0.026BPart D
Peak4.1 years to LOESITAVIG occupies a niche position in peak lifecycle with minimal Medicare utilization ($26K annual spending), suggesting a small, specialized sales and marketing team focused on dermatology or specialty segments.
Mechanism of Action
DNA Polymerase Inhibitors
Indications (3)
Worked on SITAVIG at Charter Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.